Navigation Links
Actavis Extends Portfolio With Four New Products in the U.S.
Date:2/27/2008

MORRISTOWN, N.J., Feb. 27 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, has received approval on four new products from the U.S. Food & Drug Administration.

The four products include:

Phendimetrazine tartrate tablets, 35mg: the generic equivalent of Bontril(R) tablets by Valeant Pharmaceuticals, are indicated in the adjunct management of weight loss. Annual sales of Phendimetrazine tartrate tablets had annual sales of US$3.1 million for the 12 months ending December 2007 according to IMS Health data.

Buspirone tablets, 30mg: the generic equivalent of Bristol Myers Squibb's Buspar(R). Buspirone tablets, used in the treatment of anxiety disorders, had annual sales of US$15.4 million for the 12 months ending December 2007 according to IMS Health data.

Baclofen tablets: the generic equivalent of Lioresal(R) tablets by Novartis, will be available in 10mg and 20mg strengths. Baclofen tablets are used to relax muscles and relieve pain and discomfort associated with certain nerve disorders.

Benztropine Mesylate Tablets, 0.5mg, 1mg, 2mg: are the generic equivalent to Cogentin(R). Benztropine mesylate is an antidrykinetic, which reduces the symptoms of Parkinson's disease by improving muscle control and reducing stiffness. Annual sales of Benztropine mesylate were US$12.8 million for the 12 months ending December 2007 according to IMS Health data.

Commenting on the new approvals, Terry Fullem, Vice President of Marketing and Portfolio in the U.S. said:

"These approvals signify our commitment to provide our customers with a broad and expanding pipeline. We launched 19 products in the United States in 2007 and plan to increase that number in 2008. Actavis currently has over 70 pending applications at the FDA, including a growing list of first-to-file generic products. This momentum in our development pipeline will ensure that we continue to be on the forefront of bringing new generic pro
'/>"/>

SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Actavis Confirms its Patent Challenge of Kings Avinza(R)
2. Actavis Launches Amlodipine Tablets in the U.S.
3. Actavis Launches Carvedilol Tablets in the U.S.
4. EMC Extends Innovation for VMware environments
5. The Centers for Medicare & Medicaid Services Extends LifeMasters Demonstration Project in Florida
6. BioMed Realty Trust Joint Venture Enters Into New $245 Million Construction Loan and Extends Term of Existing Loan Facility
7. Office of Administration Extends Retired State Employees Health Benefits Enrollment Period to March 21
8. Compuware Covisint Extends Commitment to Healthcare Industry with Acquisition of Hilgraeve, Inc.
9. A Little Regular Exercise Extends Mens Lives
10. Advanced Home Care Extends Its Use of Authentidates Inscrybe(TM) Healthcare Platform
11. OSHA Extends Comment Period for Lookback Review of Methylene Chloride Standard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Randy Dotinga HealthDay Reporter ... powerful drug combo may not be as effective against ... human cells suggests that one of the medications might ... study,s findings aren,t definitive, and there,s still hope for ... lumacaftor, according to the study,s senior author. "The ...
(Date:7/23/2014)... Steven Reinberg HealthDay Reporter ... obese and overweight American children and teens look in ... U.S. health officials reported Wednesday. "Being overweight or ... high blood pressure, high cholesterol and diabetes," said lead ... Centers for Disease Control and Prevention,s National Center for ...
(Date:7/23/2014)... patients if a suspicious skin lesion is painful or ... likely to be cancerous, according to a new study ... of Dermatology at Temple University School of Medicine. , ... on July 23, 2014, found that nearly 36. 9 ... while 28.2 percent involve pain. Non-melanoma skin cancers ...
(Date:7/23/2014)... 23, 2014 The next episode of ... Milwaukee, Wis. who was physically fit through childhood and ... ultimately made the heart-wrenching decision to give her son ... the past 18 years, and she punished herself by ... Featuring a unique, non-competitive approach to weight loss transformations, ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Celebrating a ... New Jersey today announced the awarding of $1,070,000 in ... special award in recognition of the Foundation’s 1,000th grant. ... to continue our tradition of supporting community-based organizations that ... quality of life in the Garden State,” said Robert ...
Breaking Medicine News(10 mins):Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 3Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2Health News:“Extreme Weight Loss”: Cassie’s journey begins at the University of Colorado Anschutz Health and Wellness Center 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 4Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 5
... to provide guidance for global market development.SUNNYVALE, Calif. ... Systems, Inc., a technology leader in developing novel ... of Hironori Yamamoto, MD, PhD, of Jichi Medical ... privileged that Dr. Yamamoto has elected to join ...
... Other Health Insurers Are Illegally Denying Treatment to Autistic ... being released by Consumer Watchdog: Who: Guillermo Arce , ... father of Frank Nagle , Harvey Rosenfield ... insurance reform initiative, Proposition 103 , Scott Glovsky ...
... how autoimmune diseases are triggered , , TUESDAY, Feb. ... by exposure to pig brains might help researchers learn ... More than a year ago, workers at pork processing ... and tingling in their arms and legs. Their common ...
... MDVN ) today announced that it will ... on Wednesday, February 25, at 4:30 p.m. Eastern Time ... ongoing Phase 1-2 clinical trial of the Company,s novel ... Scher, M.D., principal investigator of the trial and chief ...
... TrinityCare Senior Living, Inc. (formerly OTCBB: JKAN) (the ... facilities, today announced that its Board of Directors has ... the public entity from July 31st to December 31st. ... and re-incorporation was completed and approved on February 16, ...
... HARRISBURG, Pa., Feb. 24 Swiss Villa Dairy Farm ... monocytogenes contamination and resumed sales of raw milk on ... milk is milk that has not been pasteurized. ... have samples of their milk laboratory tested due to ...
Cached Medicine News:Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 2Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 3Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 4Health News:Parents of Autistic Children Fight Back - Warn HMO Regulator Against Changing Rules to Favor Insurers That Deny Access to Medical Treatment 2Health News:Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients 2Health News:TrinityCare Senior Living, Inc. Changes Fiscal Year End to December 31st 2
(Date:7/23/2014)... , July 23, 2014 Today,s U.S. ... to treat patients with relapsed chronic lymphocytic leukemia ... (SLL) is a significant advance for patients with ... goes by the trade name Zydelig®, is a ... is highly expressed in many B-cell malignancies and ...
(Date:7/23/2014)... ALTO, Calif., July 23, 2014  Varian Medical Systems ... earnings of $1.02 per diluted share in the third ... impacted by about $0.06 per diluted share due to ... portion of Varian,s existing equity investment in Augmenix, a ... company-wide revenues totaled $748 million for the third quarter ...
(Date:7/23/2014)... , July 23, 2014 UBM Medica US ... a new online community and information resource for neurologists ... and treat their patients with neurological disorders . ... an aging population, necessitates greater access to dedicated information ... statistics on neurological conditions include: , 1 ...
Breaking Medicine Technology:The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 10UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3
... Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: ... on developing topically administered products using its proprietary transdermal ... exploring strategic alternatives aimed at enhancing shareholder value with ... Advisors, a division of KEMA Partners.  The goal ...
... 31, 2011 Nephros, Inc. (OTC Bulletin Board: ... marketing filtration products for therapeutic applications, infection control, and ... Form S-1 for its previously announced rights offering to ... 2011 by the Securities and Exchange Commission. ...
Cached Medicine Technology:Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 2Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 3Nephros Rights Offering Registration Statement Declared Effective 2Nephros Rights Offering Registration Statement Declared Effective 3Nephros Rights Offering Registration Statement Declared Effective 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: